SANDOZ

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
  An AstraZeneca drug reduced the dangerous flare-ups that worsen COPD in a pair of late-stage trials
  stat · 29d ago
• Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
  The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.
  biospace · 29d ago
• Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
  LONDON — Sandoz is betting big on its newly formed biosimilar unit, as it reveals plans to grow its pipeline there by more than sevenfold and also invests $300 million in a new biosimilar manufactu…
  endpoints · 1mo ago
• AstraZeneca scores in lung cancer; Sandoz inks a China deal
  A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
  biopharma_dive · 1mo ago
• Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
  The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
  biospace · 1mo ago
• STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
  AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacks
  stat · 1mo ago
• Austria’s new growth fund could further bolster its dynamic biotech innovation economy
  The national growth vehicle isn’t biotech‑dedicated, but channeling capital toward life sciences would amplify Austria’s strong research hubs, nondilutive funding landscape and reputation as a cham…
  biospace · 1mo ago
• STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
  In today's Pharmalittle newsletter, a Medicare pilot and orphan drugs, Pfizer cutbacks, and more.
  stat · 2mo ago
• STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
  Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug
  stat · 2mo ago
• STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
  A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
  stat · 2mo ago